fbpx

Day

December 8, 2015
Ness Ziona, Israel - Dec 7, 2015 - Atox Bio, developer of immunomodulatory therapeutics for rapidly-progressing infectious diseases in critically ill patients, today announced that it has enrolled the first patient in its Phase 3 study to evaluate AB103 - the first-ever candidate developed for the treatment of Necrotizing Soft Tissue Infections (NSTIs), also known...

News

Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge